-

06:10:49 AM

VERV Stock News

VERV - Verve Therapeutics Inc

05/10/22 6:30 AM

Nasdaq : VERV

earningsclinical trial

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results

Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable

RHEA-AI

neutral

05/09/22 6:30 AM

Nasdaq : VERV

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022

VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to Mean 68% Reduction in Plasma LDL-C in NHPs Out to One-Year with Good

RHEA-AI

very positive

05/04/22 6:30 AM

Nasdaq : VERV

conferences

Verve Therapeutics to Participate in Upcoming May Investor Conferences

Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate

RHEA-AI

neutral

04/26/22 6:30 AM

Nasdaq : VERV

Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia

Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing at 500X Coverage of Primary Human Liver Cells Treated with VERVE-101 Demonstrated No Increased

RHEA-AI

neutral

04/04/22 6:30 AM

Nasdaq : VERV

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

RHEA-AI

neutral

03/24/22 6:30 AM

Nasdaq : VERV

conferences

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief

RHEA-AI

neutral

03/14/22 6:30 AM

Nasdaq : VERV

earnings

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results

Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing Approach and Proprietary Lipid Nanoparticle Delivery System Cash, Cash Equivalents

RHEA-AI

neutral

02/23/22 6:30 AM

Nasdaq : VERV

conferences

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will

RHEA-AI

neutral

01/10/22 6:30 AM

Nasdaq : VERV

clinical trial

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs

RHEA-AI

very positive

01/03/22 6:30 AM

Nasdaq : VERV

conferences

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at

RHEA-AI

neutral